Unknown

Dataset Information

0

Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors.


ABSTRACT: Human parainfluenza virus (hPIV) infections are a major cause of respiratory tract illnesses in children, with currently no available vaccine or drug treatment. The surface glycoprotein haemagglutinin-neuraminidase (HN) of hPIV has a central role in the viral life cycle, including neuraminic acid-recognising receptor binding activity (early stage) and receptor-destroying activity (late stage), which makes it an ideal target for antiviral drug disovery. In this study, we showed that targeting the catalytic mechanism of hPIV-1 HN by a 2?,3?-difluoro derivative of the known hPIV-1 inhibitor, BCX 2798, produced more potent inhibition of the neuraminidase function which is reflected by a stronger inhibition of viral replication. The difluorosialic acid-based inhibitor efficiently blocked the neuraminidase activity of HN for a prolonged period of time relative to its unsaturated neuraminic acid (Neu2en) analogue, BCX 2798 and produced a more efficient inhibition of the HN neuraminidase activity as well as in vitro viral replication. This prolonged inhibition of the hPIV-1 HN protein suggests covalent binding of the inhibitor to a key catalytic amino acid, making this compound a new lead for a novel class of more potent hPIV-1 mechanism-based inhibitors.

SUBMITTER: Eveno T 

PROVIDER: S-EPMC6563277 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting Human Parainfluenza Virus Type-1 Haemagglutinin-Neuraminidase with Mechanism-Based Inhibitors.

Eveno Tanguy T   Dirr Larissa L   El-Deeb Ibrahim M IM   Guillon Patrice P   von Itzstein Mark M  

Viruses 20190505 5


Human parainfluenza virus (hPIV) infections are a major cause of respiratory tract illnesses in children, with currently no available vaccine or drug treatment. The surface glycoprotein haemagglutinin-neuraminidase (HN) of hPIV has a central role in the viral life cycle, including neuraminic acid-recognising receptor binding activity (early stage) and receptor-destroying activity (late stage), which makes it an ideal target for antiviral drug disovery. In this study, we showed that targeting the  ...[more]

Similar Datasets

| S-EPMC5495814 | biostudies-literature
| S-EPMC3255505 | biostudies-literature
| S-EPMC1866072 | biostudies-literature
| S-EPMC2519694 | biostudies-literature
| S-EPMC2737897 | biostudies-literature
| S-EPMC6072455 | biostudies-literature
| S-EPMC3754076 | biostudies-literature
| S-EPMC5683071 | biostudies-literature
| S-EPMC3812707 | biostudies-literature
| S-EPMC4026691 | biostudies-literature